Key result
Intravenous gammaglobulin treatment in Kawasaki disease reduces cytokine secretion and reverses endothelial cell activation, supporting a role for immune-mediated injury in its pathogenesis.
Why the study?
Does intravenous gammaglobulin (IVGG) reduce cytokine-mediated vascular endothelial activation and prevent coronary artery abnormalities in infants and children with Kawasaki disease?
Does intravenous gammaglobulin (IVGG) reduce cytokine-mediated vascular endothelial activation and prevent coronary artery abnormalities in infants and children with Kawasaki disease?
The reversal of cytokine-mediated vascular endothelial activation by IVGG supports the role of immune-mediated injury in the pathogenesis of Kawasaki disease.
Immune activation findings in KD remain hypothesis-generating; leaves open targeted therapies for CA complications in Level 5 data.
Kawasaki disease (KD) is an acute febrile illness of infancy and early childhood characterized by diffuse vasculitis. Although the disease is generally self-limited, up to 30% of untreated patients with KD may develop coronary artery (CA) abnormalities. The acute phase of KD is characterized by marked activation of the immune system leading to increased cytokine production by immune effector cells, the induction of activation antigens on their vascular endothelium and the generation of lytic antibodies directed against vascular endothelial cells (EC) stimulated with cytokines. Treatment with intravenous gammaglobulin (IVGG) usually rapidly reduces acute clinical symptoms and prevents CA abnormalities. Immunologically, successful IVGG treatment is associated with decreased lymphocyte activation, reduced cytokine secretion and the loss of cytokine induced expression of leukocyte adhesion molecules on vascular endothelium. The association between improvement of clinical symptoms with the reduction of cytokine secretion, and reversal of EC activation supports a role for immune mediated injury to cytokine induced EC antigens in the pathogenesis of this disorder.
No takes yet. Share an insight, caveat, or question.
Donald Y.M. Leung (1991) conducted a review in Kawasaki disease. Intravenous gammaglobulin (IVGG) was evaluated. Intravenous gammaglobulin treatment in Kawasaki disease reduces cytokine secretion and reverses endothelial cell activation, supporting a role for immune-mediated injury in its pathogenesis.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: